<DOC>
	<DOCNO>NCT00691028</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety pharmacokinetics maintenance treatment 3mg/kg , 6mg/kg 10mg/kg TA-650 combination methotrexate ( MTX ) three infusion ( weeks-0 , 2 , 6 ) 3mg/kg Rheumatoid Arthritis ( RA ) show insufficient response MTX .</brief_summary>
	<brief_title>Efficacy Safety Increased Dose TA-650 ( Infliximab ) Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients active RA spite stable dose MTX Having receive infliximab past Having history serious infection cause hospitalization within 6 month registration Having active tuberculosis Having complication history malignancy within 5 year registration</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>RA</keyword>
	<keyword>Infliximab</keyword>
	<keyword>TA-650</keyword>
	<keyword>Remicade</keyword>
</DOC>